CONCLUSIONS: The November 2021 reform was associated with a rapid and sustained expansion of adult methylphenidate use over the 3 years following the reform, primarily through increased treatment initiation, suggesting that prior regulatory constraints largely explained historically low treatment rates. Longer follow-up will be needed to assess whether this trajectory is maintained.
